93 related articles for article (PubMed ID: 19207027)
1. Rituximab not affected by statins?
Pharmacogenomics; 2009 Feb; 10(2):259. PubMed ID: 19207027
[No Abstract] [Full Text] [Related]
2. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
Winiarska M; Bil J; Wilczek E; Wilczynski GM; Lekka M; Engelberts PJ; Mackus WJ; Gorska E; Bojarski L; Stoklosa T; Nowis D; Kurzaj Z; Makowski M; Glodkowska E; Issat T; Mrowka P; Lasek W; Dabrowska-Iwanicka A; Basak GW; Wasik M; Warzocha K; Sinski M; Gaciong Z; Jakobisiak M; Parren PW; Golab J
PLoS Med; 2008 Mar; 5(3):e64. PubMed ID: 18366248
[TBL] [Abstract][Full Text] [Related]
3. Interaction between statins and rituximab in non-Hodgkin's lymphoma.
Rabinowitz I
J Clin Oncol; 2008 Nov; 26(33):5486; author reply 5486. PubMed ID: 18936467
[No Abstract] [Full Text] [Related]
4. [Resistance to rituximab and CD20 mutation].
Terui Y; Hatake K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():416-23. PubMed ID: 17474440
[No Abstract] [Full Text] [Related]
5. Rituximab in CD20 positive multiple myeloma.
Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau JL; Bataille R;
Leukemia; 2007 Apr; 21(4):835-6. PubMed ID: 17268523
[No Abstract] [Full Text] [Related]
6. Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.
Barker CA; Yahalom J
J Clin Oncol; 2010 Aug; 28(24):e426; author reply e427-8. PubMed ID: 20566995
[No Abstract] [Full Text] [Related]
7. CD20 as a target for therapeutic type I and II monoclonal antibodies.
Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ
Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657
[TBL] [Abstract][Full Text] [Related]
8. Rituximab and statins.
Carver JR; Johnson T; Schuster SJ
J Clin Oncol; 2010 Oct; 28(30):e611; author reply e612. PubMed ID: 20805449
[No Abstract] [Full Text] [Related]
9. Is statin use really associated with efficacy of rituximab?
Asai H; Yokoyama M; Terui Y; Ennishi D; Takeuchi K; Hatake K
J Clin Oncol; 2010 Aug; 28(24):e424-5; author reply e427-8. PubMed ID: 20567023
[No Abstract] [Full Text] [Related]
10. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
[TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 antibody treatment in refractory Class IV lupus nephritis.
Carroll RP; Brown F; Kerr PG
Nephrol Dial Transplant; 2007 Jan; 22(1):291-3. PubMed ID: 17095581
[No Abstract] [Full Text] [Related]
13. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma.
Lossos IS; Morgensztern D; Blaya M; Alencar A; Pereira D; Rosenblatt J
Leuk Lymphoma; 2007 Aug; 48(8):1630-2. PubMed ID: 17701596
[No Abstract] [Full Text] [Related]
14. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
15. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
[No Abstract] [Full Text] [Related]
16. Severe pulmonary complications after initial treatment with Rituximab for the Asian-variant of intravascular lymphoma.
Wu SJ; Chou WC; Ko BS; Tien HF
Haematologica; 2007 Jan; 92(1):141-2. PubMed ID: 17229654
[TBL] [Abstract][Full Text] [Related]
17. [Rituximab and hematological malignancy].
Hatake K; Mishima Y; Terui Y
Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
[TBL] [Abstract][Full Text] [Related]
18. Regression of cutaneous intravascular lymphoma with rituximab.
Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T
Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938
[TBL] [Abstract][Full Text] [Related]
19. [Development of monoclonal antibody therapy for brain tumors].
Mishima K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():569-77. PubMed ID: 16201583
[No Abstract] [Full Text] [Related]
20. About the old and the new: gallium-67 scintigraphy to rituximab for lymphoma.
DeNardo GL
Cancer Biother Radiopharm; 1999 Aug; 14(4):235-6. PubMed ID: 10850308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
